Grafalon

ApprovedSmall molecule

FFundación Canaria de Investigación Sanitaria

Grafalon is one of 63 small molecule programs targeting Kidney Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Kidney TransplantApproved

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

62 2

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 3

Clolar

GGenzyme, a Sanofi Company

Phase 3

21 4

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

12 5

Velcade

SShilpa Grover, MD, MPH

Phase 3

11 6

Alkeran

AApotex Inc.

Phase 3

7 7

Decadron

AAspen Global Incorporated

Phase 3

5 8

Astplayer

AAstex Pharmaceuticals, Inc.

Phase 3

3 9

Tabloid

Akero Therapeutics

Phase 3

2 10

Lenograstim

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Acute Myeloid Leukemia

NCT06083129

Q2 2030

Phase 2/3Recruiting

Allogeneic Stem Cell Transplantation

NCT01949129

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06083129·324 enrolled

Kidney Transplant1 trial

Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)

Unknown status·FFundación Canaria de Investigación Sanitaria·Phase 4·NCT04936282·80 enrolled

Allogeneic Stem Cell Transplantation1 trial

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Recruiting·SSt. Anna Kinderkrebsforschung·Phase 2/3·NCT01949129·1,800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Grafalon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Grafalon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Grafalon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundación Canaria de Investigación Sanitaria company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFundación Canaria de Investigación Sanitaria

Grafalon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2030

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Kidney Transplant1 trial

Allogeneic Stem Cell Transplantation1 trial

References

Drug Info

Quick Facts

Related News